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Abstract
OBJECTIVE: To compare the efficacy of an acu-
puncture regimen for persistent allergic rhinitis
(PER), aimed at improving a patient's mind or Shen
in Traditional Chinese Medicine, to that of a sec-
ond-generation H1-receptor antagonist, cetirizine
hydrochloride.
METHODS: This multicenter, randomized, con-
trolled clinical trial on PER will be conducted at
three institutions in China. The total study period
will be 9 weeks. After a 1-week preparatory screen-
ing period, 240 eligible participants with PER will
be randomized to receive acupuncture or pharma-
cotherapy (1∶1) for 4 weeks with a 4-week fol-
low-up. The primary outcome will be changes in
7-day average total nasal symptom score. Second-
ary outcome measures include rhinoconjunctivitis
quality of life questionnaire score and total non-na-
sal symptom score.
RESULTS: The presence and seriousness of psycho-
logical and emotional impairments should be con-
sidered in therapeutic programs for allergic rhinitis.
No clinical trial for treating allergic rhinitis via acu-
puncture regulation of psychological and emotion-
al activities has been reported.
CONCLUSION: The findings of the trial will allow us
to determine the effects of the mind (Shen)-regula-
tion treatment approach. We will also be able to
confirm if the effects of acupuncture are equivalent
to those of the conventional drug cetirizine hydro-
chloride.
© 2014 JTCM. All rights reserved.
Key words: Acupuncture; Rhinitis; Psychological
and emotional impairment; Mind (Shen)-regula-
tion; Randomized controlled trial
INTRODUCTION
Allergic rhinitis (AR) causes major illness and disability
worldwide. Patients from all countries, all ethnic
groups, and all ages suffer from AR.1 The management
of AR includes allergen avoidance, pharmacotherapy,
immunotherapy, and surgery. Allergen avoidance and
pharmacotherapy are first-line treatments for AR, but
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recurrence of the disorder makes medication less effec-
tive over time. Although a new generation of medica-
tions with decreased side effects has been developed,
side effects have not been completely eliminated.2
AR is called "Bi Qiu" (running nose) in Traditional
Chinese Medicine (TCM) literature. Acupuncture has
been used to treat AR since the first TCM classic,
Huang Di Nei Jing.3 In recent years, clinical trials have
been conducted to evaluate the efficacy of acupuncture
for AR. Some trials showed that active acupuncture
was more effective than sham acupuncture in decreas-
ing the symptom scores for persistent allergic rhinitis
(PER) and increasing the number of symptom-free
days.4,5 In conjunction with routine care, acupuncture
leads to clinically relevant and persistent benefits,6 is
cost-effective according to international benchmarks,7
and has shown no serious adverse effects.4However, be-
cause of experimental design weaknesses, such as lack
of sham or placebo controls, lack of clear selection cri-
teria, and inclusion of a mixture of different allergic
rhinitis categories, the conclusions made by these trials
are weak. Other problems in previous studies include
insufficient details on acupuncture treatment proce-
dures, particularly those related to rationales for acu-
point selection and needling techniques.8 A systematic
review of the clinical effectiveness of acupuncture for
AR published in 2008 concluded that "there is current-
ly insufficient evidence to support or refute the use of
acupuncture in patients with AR. It is not possible to
recommend acupuncture as a proven treatment for AR
on the basis of published evidence."9 Consequently,
2010 Allergic Rhinitis and its Impact on Asthma
(ARIA) guidelines suggest clinicians not administer
and patients not use acupuncture.10
However, trial design weakness and a lack of detailed
descriptions of acupuncture treatment procedures
could keep the modality from being recommended for
AR. Better designed clinical acupuncture trials should
be conducted, and reports of study results should con-
form to the Standards for Reporting Interventions in
Clinical Trials of Acupuncture.11 Additionally, new
treatment protocols should be developed to improve
acupuncture treatment effects so that choices besides
pharmacotherapy can be offered to AR patients.
Psychological and emotional dysfunction and
allergic rhinitis
Research reveals an interaction between psychological
factors and allergic diseases. Allergic diseases can influ-
ence the psychological status of individuals to produce
imbalances or other disturbances.12,13 Marshall et al 14
found that seasonal allergic rhinitis patients reported
higher levels of general and mental but not physical fa-
tigue, reduced motivation, and significant mood chang-
es during ragweed season. A similar study also conduct-
ed by Marshall et al 15 showed that AR patients experi-
enced subtly slowed cognitive processing speeds and
some had difficulty with working memory during rag-
weed season. Kremer et al 16 reported that psychologi-
cal wellbeing was significantly impaired in patients
with symptomatic allergic rhinitis, as shown by higher
scores in feelings of insufficiency, complaints of somati-
zation, sleep disturbances, and depressive feelings.
Leger et al 17 found that patients with moderate to se-
vere symptoms of intermittent allergic rhinitis or PER
suffered from impaired sleep, and all dimensions of
sleep were involved. Bavbek et al 18 assessed the psycho-
logical status of AR patients and found statistically sig-
nificant differences between patients and controls in all
subscales of the Symptom Checklist-90 (SCL-90), par-
ticularly in somatization, depression, and general symp-
tom index subscales. A study conducted in China also
used SCL-90 to investigate the psychological status in
AR patients and got a similar result.19 Sansone and San-
sone20 found that the majority of studies indicate associ-
ations between allergies and anxiety and mood syn-
dromes in their review of PubMed and PsycINFO da-
tabases. For example, 97.1% of individuals in 10 of 12
studies on depressive syndromes expressed a positive re-
lationship between allergy symptoms and some type of
depressive syndrome. Moreover, 99.9% of individuals
in nine of 11 studies on anxiety syndromes decisively
expressed a positive relationship between allergy symp-
toms and anxiety syndromes.
On the other hand, allergic symptoms can be triggered
and worsened by several psychological factors, includ-
ing stress. Wright et al 21 suggested that psychological
stress should be conceptualized as a social pollutant
that can be "breathed" into the body to disrupt a num-
ber of physiological pathways, just as air pollutants and
other physical toxicants can lead to increased risk of at-
opy. Stress might have independent effects in addition
to its influence on atopy through its enhancement of
neuroimmune responses to other environmental fac-
tors that operate through similar pathways. Nishioka et
al 22 found that exposure to acute restraint stress inhib-
its antigen-specific antibody production in mice. This
response suggests that acute stress has the potential to
modulate the initiation of AR. A survey also showed
that shy young adults had a higher frequency of hay fe-
ver than do extremely outgoing individuals.23 Investiga-
tions into the personality traits of AR patients indicate
a correlation between AR and poorer psychological
functioning compared with control individuals.24,25
Kiecolt-Glaser et al 26 observed the effects of stress and
anxiety on immediate and late-phase skin test respons-
es in AR and concluded that stress and anxiety can en-
hance and prolong AR symptoms.
Although the relationship between psychological fac-
tors and AR is recognized, few answers are available re-
garding whether regulating patient psychological and
emotional state can improve the therapeutic effects of
AR treatment.
Psychological factors and emotions are ascribed to
mind, or Shen, in TCM. The aim of the current study
is to assess the efficacy of an acupuncture regimen for AR
that adds Shen-regulating points to the traditionally
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used acupoint formula to improve psychological and
emotional states in PER patients. The effect of this reg-
imen will be compared with that of pharmacotherapy.
METHODS
Trial design
This will be a multicenter, randomized, controlled clin-
ical trial comparing the effect of Shen-regulating acu-
puncture with that of pharmacotherapy in PER. It was
registed in Chinese Clinical Trial Register ChiC-
TR-TRC-11001245. It will be conducted in three in-
stitutions in China: Dongzhimen Hospital Affiliated to
Beijing University of Chinese Medicine, Beijing Ton-
gren Hospital, and Beijing Hospital of Traditional Chi-
nese Medicine. The total study period will be 9 weeks.
After a 1-week preparatory screening, participants will
be randomized to receive either acupuncture or phar-
macotherapy for 4 weeks with a 4-week follow-up peri-
od (Figure 1).
Recruitment
Participants will be recruited through a notice posted
in the research hospitals and nearby communities. Af-
ter screening for eligibility, qualified patients will be in-
formed of the trial design. They will then give their
written informed consent and undergo a week-long
preparatory screening consisting of routine blood tests,
creatinine (Cr), blood urea nitrogen (BUN), alanine
aminotransferase (ALT), and aspartate aminotransfer-
ase (AST). These are required as safety indicators for
the intervention. Eosinophil (EOS) count and immu-
noglobulin E (IgE) are also required as efficacy and
mechanism indicators, and patients will be asked to
keep a diary on nasal and non-nasal symptoms (TNSS
and TNNSS) for 1 week. Participants who are quali-
fied but have taken PER symptomatic relief medica-
tion in the 14 days before preparatory screening will be
instructed to stop therapy for 14 days, after which they
may undergo preparatory screening. All qualified pa-
tients will be provided with the usual care instructions
for AR. After the 1-week preparatory screening period,
eligible patients will be enrolled in the trial. Ineligible
patients will be thanked and offered routine treatment.
Recruitment will continue until recruitment targets are
achieved.
Inclusion criteria
Included patients must be diagnosed with AR plus per-
sistent PER and classified as moderate to severe de-
pending on the severity of symptoms and quality of life
outcomes.1 Participants must be between 18 and 60
years old, be well informed about the study, and have
signed the written informed consent form. Their 7-day
mean TotalNasal SymptomScore (TNSS)must be ≥4.27
Figure 1 Study flow chart
Outcome assessment at the end of 4th week of follow-up
Outcome assessment at the end of 4th week of treatment
Outcome assessment at the end of 2nd week of treatment
Patient recruitment
Eligibility screening
1-week preparatory screening period
Random allocation
(n=240)
Acupuncture group (n=120) Pharmacotherapy group (n=120)
3 times/week for 4 weeks 10 mg/d for 4 weeks
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Exclusion criteria
Individuals will be excluded from the study if any of
the following are applicable. (a) Patients have suffered
from diseases related to the nose, paranasal sinus, or up-
per respiratory tract such as acute paranasal sinusitis or
an upper respiratory infection within the last 14 days;
show signs of chest inflammation in an X-ray; have a
history of chronic paranasal sinusitis as shown by acces-
sory nasal cavity X-ray examination; or have had organ-
ic nasal cavity disease, have undergone nasal cavity sur-
gery, or have paroxysmal respiratory diseases such as
asthma. (b) Patients are receiving or have received treat-
ment that might influence the assessment of results in-
cluding H1 antihistamines, steroids, antihistamines, de-
congestants (nasal, oral, or ophthalmic), corticoste-
roids, or antibiotics within 14 days of enrollment; have
had specific immunotherapy or systematic hormone
therapy in the last year; have had acupuncture, moxi-
bustion, cupping, nasal inhalation of herbal medicine,
or other physical alternative medicine therapy within
the last 14 days; or have taken herbal preparations for
AR within the last 14 days. (c) Patients that have suf-
fered from mental disorders, tuberculosis, hepatitis, or
have blood Cr or AST/ALT values twice the normal
level. (d) patients that are pregnant, lactating, or plan-
ning to become pregnant. (e) Patients that have a histo-
ry of smoking more than 10 cigarettes daily over 10
consecutive years. (f ) Patients presenting with scars at
the acupoint locations or suffering from a systemic dis-
ease and are therefore considered unsuitable for acu-
puncture. (g) Patients that are determined to be unable
to cooperate in the trial.
Sample size
As we did not conduct a pilot study on acupuncture
for PER, we searched the literature for the effective rate
parameters of acupuncture in AR and used those to cal-
culate the sample size.The literature shows that the effec-
tive rate of acupuncture in most AR/acupuncture stud-
ies is between 85% and 90%,28,29 and the effective rate
of cetirizine hydrochloride for AR in China is also be-
tween 85% and 90%.30,31 Because our study is a noninferi-
ority trial, we calculated the sample size based on a
noninferiority clinical trials design. The formula used is:
N=([P0q0+P1q1]/Δ2)×(Zα+Zβ)2 (Bolton, Kim, 1997).
TypeⅠ error is controlled under 0.05, typeⅡ error is
controlled under 0.20 (power of test is 80%), the alpha
value is 5% (single-tailed), the beta value is 20%, (sin-
gle-tailed), P0=0.85, q0=0.15, P1=0.85, q1=0.15, and d=
0.15.
The results indicate that there should be 98 subjects in
each group. A 1∶1 ratio was applied to both groups.
We plan to enroll 120 participants in each group to al-
low for a 20% dropout rate.
Randomization and blindness
A central stratified block randomization will be de-
signed for this study by the central randomization sys-
tem. Stratified randomization will be performed by
each center. After inclusion of an eligible patient, re-
searchers can log into the web edition of the Central
Randomization System for Clinical Research or use the
telephone edition developed by the Clinical Research
Centre of China Academy of Chinese Medical Sciences
to get the randomized number for group assignment.
The randomized numbers are produced by professional
biostatisticians with SAS 9.3.1 software (SAS Institute
Inc., Cary, NC, USA). A total of 240 participants will
be randomized to receive acupuncture or pharmaco-
therapy at the three trial centers in a 1∶1 ratio. The
number of researchers at the three centers differs.
Therefore, the number of patients enrolled at each cen-
ter will be unequal: Dongzhimen Hospital Affiliated to
Beijing University of Chinese Medicine will have 100;
Beijing Tongren Hospital, 80; and Beijing Hospital of
Traditional Chinese Medicine, 60. The researcher per-
forming outcome assessments and the trial biostatisti-
cian analyzing the study data will be blinded to partici-
pant group allocation. However, patients and the acu-
puncturists who perform the treatment will not be
blinded due to the nature of the trial in which the pa-
tient could easily tell whether they receive acupuncture
treatment or medicine.
Intervention
Acupuncture intervention: participants in the acupunc-
ture group will be treated by certified acupuncturists at
the three centers. Acupuncture treatment will be given
three times a week for 4 weeks in a total of 12 sessions.
The treatment protocol is intended to eliminate AR
symptoms and improve patients' psychological and
mental states.
The acupuncture points used will be Yingxiang (LI
20), Yintang (GV 29), Hegu (LI 4), Dazhui (GV 14),
Feishu (BL 13), Pishu (BL 20), Shenshu (BL 23),
Ganshu (BL 18), Taichong (LR 3), and Baihui (GV
20). Acupoints are located according to the People's Re-
public of China, State Standard Name and Location of
Acupoints (GB 12346-2006).32 Needles will be 0.25 mm
(diameter) × 40 mm (length) disposables (Beijing
Zhongyan Taihe Medicine Co., Ltd., Beijing, China).
With the patient prone, the back points, Dazhui (GV
14), Feishu (BL 13), Pishu (BL 20), Shenshu (BL 23),
and Ganshu (BL 18), will be needled. After de-Qi sen-
sations are felt by the patient and acupuncturist, rein-
forcing manipulation will be performed for 30 s, then
the needles will be withdrawn.
The other five points will be needled with the patient
supine. After de Qi, the practitioner will apply even re-
inforcing and reducing manipulation for 30 s. Then,
Yintang (GV 29) and Baihui (GV 20), and bilateral
Yingxiang (LI 20) will be connected to a Han's Elec-
troacupuncture Apparatus (Nanjing Jisheng Medical
Medical Technology Co., Ltd., Nanjing, China). The 2/
100 Hz sparse-dense waves will be applied at an intensi-
ty within participants' tolerance. Needles will be re-
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tained for 20 min. During retention, the practitioner
will lift, thrust, and rotate the needles at Hegu (LI 4)
and Taichong (LR 3) for 10 s to maintain or intensify
the needle sensation.
The acupuncture treatment procedure (Table 1) will be
standardized in the three centers by a training session
conducted before the beginning of the study.
Pharmacotherapy
Participants in the pharmacotherapy group will take
10 mg of cetirizine hydrochloride (Lunan Pharmaceuti-
cal Group Corp., Linyi, China) orally once a day for
4 weeks. Patients will receive a 2-week supply of the
drug twice during the study period, the first time dur-
ing enrollment in the pharmacotherapy group and the
second at the beginning of the third week of the study.
Outcome measures
Primary outcomes: nasal symptoms will be assessed
with a 7-day average TNSS5,33 that will be reviewed by
an assessor blinded to the participants' treatment
groups at the end of the 1-week preparatory screening
period, the second and fourth weeks of treatment, and
the fourth week of the follow-up period. TNSS will be
determined by four nasal symptoms, self-assessed daily,
and recorded in a diary by participants throughout the
study.
Secondary outcomes
Quality of life will be assessed with the Rhinoconjunc-
tivitis quality of life questionnaire (RQLQ) score.34
RQLQ consists of 28 items and seven domains: activi-
ty, sleep, nasal symptoms, ocular symptoms, non-nose/
non-eye symptoms, practical problems, and emotions.
Each item is rated from 0 (not troubled) to 6 (extreme-
ly troubled). RQLQ will be assessed by researchers at
the end of the 1-week preparatory screening period,
the second and fourth weeks of treatment, and the fol-
low-up period.
Non-nasal symptoms will be assessed by the 7-day aver-
age total non-nasal symptom score (TNNSS).33
TNNSS will be self-assessed daily and recorded in a di-
ary by participants through the study. Scores will be re-
viewed by an assessor blinded to the participants' treat-
ment group at the end of the 1-week preparatory
screening period, the second and fourth weeks of treat-
ment, and the follow-up period.
The use of PER relief medication will be recorded on
the medication quantification scale during the fol-
low-up period.
Immunological state change will be assessed by EOS
count and total serum total IgE in the preparatory peri-
od and after the treatment period as an efficacy and
mechanism indicator.
Adverse events
Any unexpected events will be recorded on an adverse
event report form during the trial.
Blood, liver function, and kidney function will be test-
ed by a routine blood test, Cr, BUN, ALT, and AST
during preparatory screening and after 4 weeks of treat-
ment.
Data collection
Data will be collected throughout the trial. TNSS and
TNNSS will be collected from participants' diaries dur-
ing their visits.
Statistical analysis
Baseline and efficacy data will be respectively analyzed
with the full analysis set and per-protocol set. Adverse
effect data will be analyzed with the safety set.
Statistical analyses will be performed using the SPSS
statistical package program (ver. 9.1.3, SAS Institute
Inc., Cary, NC, USA), and the level of significance will
be established at α=0.05).
Baseline analyses
Demographic data (age, sex ratio, duration of PER,
and family history of PER) and clinical characteristic
data (TNNS, TNNSS, and RQLQ) of study partici-
pants will be collected before randomization. Acupunc-
ture and pharmaceutical group data will be compared
to identify potential imbalances not accounted for by
Acupoint
Yingxiang (LI 20)
Yintang (GV 29)
Hegu (LI 4)
Dazhui (GV 14)
Feishu (BL 13)
Pishu (BL 20)
Shenshu(BL 23)
Ganshu (BL 18)
Taichong (LR 3)
Baihui (GV 20)
Angle and direction
Transversely, along the nasolabial sulcus towards the root of nose
Transversely, downward toward the nose
Perpendicular to the skin
Perpendicular to the skin
Obliquely toward the spine
Obliquely toward the spine
Perpendicular to the skin
Obliquely toward the spine
Perpendicular to the skin
Transversely, anterior to the forehead
Depth (mm)
13-26
13-21
13-26
21-32
13-21
13-21
13-26
13-21
13-21
13-21
Table 1 Acupoints and needling procedure
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randomization. The Chi-square test will be used for de-
mographic enumeration data, while the student's t-test
will be used for measurement data. Student's t-test or
Wilcoxon rank-sum test will be used for clinical charac-
teristic data.
Efficacy analysis of outcomes
All data will be analyzed descriptively. Changes in
TNSS, TNNSS, RQLQ, EOS, and total serum IgE of
the two groups will be compared with the student's
t-test or Wilcoxon rank-sum test. If there are baseline
differences between the two groups, ANOVA will be
used.
Safety analysis
Frequency of adverse events in the two groups will be
compared with the Chi-square test or Fisher's exact test.
Data management
Researchers performing outcome measurements will en-
ter the collected data into case report forms. Data from
all centers will be pooled and randomized according to
demographic baseline characteristics, effectiveness, and
safety observations. Regular data monitoring will be
conducted for quality control.
DISCUSSION
AR includes more than the classical symptoms of sneez-
ing, rhinorrhea, and nasal obstruction. AR is also asso-
ciated with mental and psychological problems.1 Pa-
tients may suffer from mental fatigue, mood changes,14,15
cognitive impairment, and sleep problems.16,17 AR is as-
sociated with higher rates of depression and anxiety dis-
order, and outpatient healthcare expenditures for pa-
tients are 207 USD higher on average annually when
AR and anxiety disorder are comorbid and 363 USD
when AR and depression are comorbid.18,20,35 Therefore,
the presence and seriousness of these mental and psy-
chological impairments should be taken into consider-
ation in therapeutic programs for allergic rhinitis.36
The routine acupuncture treatment for AR has tradi-
tionally focused on the nasal symptoms without consid-
eration of possible mental and psychological impair-
ments. In an authoritative TCM textbook, AR is attrib-
uted to Lung, Spleen, and Kidney deficiency. Exoge-
nous pathological factors, Wind, and Cold invade the
Lung and affect the nose, resulting in nasal symptoms
such as rhinorrhea, sneezing, nasal congestion, and na-
sal itching.37 Therefore, we selected Yingxiang (LI 20)
and Yintang (GV 29), local points around the nose, to
relieve nasal symptoms; Hegu (LI 4) and Dazhui (GV
14), to expel wind and cold; and Feishu (BL 13), Pishu
(BL 20), and Shenshu (BL 23), the Back-Shu points of
the Lung, Spleen, and Kidney, respectively, to regulate
those organs. Based on our understanding of the recip-
rocal effects of mental and psychological factors and al-
lergic symptoms, we will add points that regulate the
mind and improve psychological wellbeing. In TCM
theory, emotions and psychological factors are ascribed
to mind (Shen). Therefore, points that regulate Shen
might help to regulate emotion and improve psycholog-
ical activity. The Liver, in TCM, ensures the smooth
flow of Qi, which has a deep influence on the emotion-
al state,38 and the Brain is where the primordial Shen re-
sides. Therefore, these two organs actively regulate
Shen. The Shen-regulating points we will use are Gans-
hu (BL 18), the Back-Shu points of Liver; Taichong
(LR 3), the Yuan-source points of the Liver Channel;
and Baihui (GV 20), a local point for the Brain and a
crossing point of Governor Vessel and Liver Channel.
These three points are related to Liver and Brain func-
tion and are believed to calm the mind and regulate
the emotions in TCM theory. Consequently, we hy-
pothesize that they will regulate psychological and emo-
tional imbalance in AR patients.
Cetirizine hydrochloride, a second-generation H1-re-
ceptor antagonist, works to treat allergy symptoms by
decreasing histamine in the body. Though not recom-
mended as the first choice therapy for moderate to se-
vere persistent rhinitis in ARIA,1 it is the first-line med-
icine for AR in China.
To our knowledge, no AR clinical trial evaluating acu-
puncture regulation of patients' psychological and emo-
tional activities has been reported.
The findings of the trial will allow us to determine the
effects of the mind (Shen)-regulation treatment ap-
proach, and we anticipate discovering whether acu-
puncture is equivalent to those of the conventional
drug cetirizine hydrochloride.
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